Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the anticipated switch of second-generation antihistamines from prescription to over-the-counter (OTC) status in each of the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will lead to increases in the number of patients opting to self medicate with nonprescription therapies rather than present to a physician for diagnosis and treatment. As a result, the diagnosis and drug- treatment rates in each of the major markets will decrease in the next ten years.

"When Schering-Plough's Claritin switched from prescription to OTC status in the United States in 2002, it marked the beginning of a precipitous decline for the prescription-based allergic rhinitis market," said Melissa Stolper, analyst at Decision Resources, Inc. "This switch marked the first time a nonsedating product of this type could be purchased without a prescription in the United States, which leads the seven markets in terms of allergic rhinitis prevalence and prescription drug sales."

The new Pharmacor study entitled Allergic Rhinitis finds that anticipated switches in prescribing status of several oral second-generation antihistamines, including fexofenadine (Allegra/Telfast) and desloratadine (Clarinex/Aerius/Neoclarityn), will have a less dramatic effect on the European prescription drug market than they will in the United States, because European physicians prescribe OTC products to patients.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Use of Insulin for Treatment of Type 2 Diabetes Increasing as a First-Line Treatment Option

View Now